CAR T cell with two CDs (CD28 and 4-1BB) exhibited superior proliferation capacity and anti-tumor function in treating multiple myeloma and relapsed/refractory non-Hodgkin's lymphoma compared with CAR T cell with CD28,27,28 while the third-generation of CAR T cell did not present stronger anti-tumor ability in prostate and pancreatic cancers.29 The gene discussed is CD28; the disease is plasma cell myeloma.